Access the full text.
Sign up today, get DeepDyve free for 14 days.
Yan Wang, K. Yamaguchi, T. Wada, K. Hata, Xuejian Zhao, T. Fujimoto, T. Miyagi (2002)
A Close Association of the Ganglioside-specific Sialidase Neu3 with Caveolin in Membrane Microdomains*The Journal of Biological Chemistry, 277
K. Ohmi, D. Greenberg, K. Rajavel, S. Ryazantsev, H. Li, E. Neufeld (2003)
Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIBProceedings of the National Academy of Sciences of the United States of America, 100
G. David, Xiaoyang Bai, B. Schueren, J. Cassiman (1992)
Developmental changes in heparan sulfate expression: in situ detection with mAbsThe Journal of Cell Biology, 119
J. Dowson, H. Wilton-Cox, A. Oldfors, P. Sourander (2004)
Autofluorescence emission spectra of neuronal lipopigment in mucopolysaccharidosis (Sanfilippo's syndrome)Acta Neuropathologica, 77
E. Monti, M. Bassi, N. Papini, M. Riboni, M. Manzoni, B. Venerando, Gianluigi Croci, A. Preti, A. Ballabio, G. Tettamanti, G. Borsani (2000)
Identification and expression of NEU3, a novel human sialidase associated to the plasma membrane.The Biochemical journal, 349 Pt 1
G. Constantopoulos, Khalid Iqbal, A. Dekaban (1980)
Mucopolysaccharidosis Types IH, IS, II and IIIA: Glycosaminoglycans and Lipids of Isolated Brain Cells and Other Fractions from Autopsied TissuesJournal of Neurochemistry, 34
H. Nioka, K. Matsumura, S. Nakasu, J. Handa (2005)
Immunohistochemical localization of glycosaminoglycans in experimental rat glioma modelsJournal of Neuro-Oncology, 21
Y Higashi, S Murayama, P Pentchev, K Suzuki (1991)
Neuropathology in brain research
Christian Oehler, Jürgen Kopitz, Michael Cantz (2002)
Substrate Specificity and Inhibitor Studies of a Membrane-Bound Ganglioside Sialidase Isolated from Human Brain Tissue, 383
K. Wisniewski, R. Rudelli, M. Laure-Kamionowska1, G. Sklower, Jr. Houck, P. Kieras, H. Ramos, H. Wisniewski, Braak (1985)
Sanfilippo Disease, Type A with some Features of Ceroid LipofuscinosisNeuropediatrics, 16
Yu Liang, M. Häring, P. Roughley, R. Margolis, R. Margolis (1997)
Glypican and Biglycan in the Nuclei of Neurons and Glioma Cells: Presence of Functional Nuclear Localization Signals and Dynamic Changes in Glypican During the Cell CycleThe Journal of Cell Biology, 139
T. Dohi, G. Nores, S. Hakomori (1988)
An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.Cancer research, 48 20
Robert Yu (1994)
Development regulation of ganglioside metabolism.Progress in brain research, 101
D. Siegel, S. Walkley (1994)
Growth of Ectopic Dendrites on Cortical Pyramidal Neurons in Neuronal Storage Diseases Correlates with Abnormal Accumulation of GM2 GangliosideJournal of Neurochemistry, 62
M. Bhaumik, V. Muller, T. Rozaklis, Johnson Linda, K. Dobrenis, Riddhi Bhattacharyya, S. Wurzelmann, Peter Finamore, J. Hopwood, S. Walkley, P. Stanley (1999)
A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome).Glycobiology, 9 12
E. Birkenmeier, M Davisson, W Beamer, R. Ganschow, C. Vogler, B. Gwynn, K. Lyford, L. Maltais, C. Wawrzyniak (1989)
Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency.The Journal of clinical investigation, 83 4
SU Walkley, ME Haskins, RM Shull (1988)
Alterations in neuron morphology in mucopolysaccharide storage disorders, 75
H. Li, Wei-hong Yu, N. Rozengurt, Hui-Zhi Zhao, K. Lyons, S. Anagnostaras, M. Fanselow, Kunihiko Suzuki, M. Vanier, E. Neufeld (1999)
Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase.Proceedings of the National Academy of Sciences of the United States of America, 96 25
土肥 多恵子 (1989)
An IgG[3] monoclonal antibody established after immunization with G[M3] lactone : immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo
S. Walkley (1998)
Cellular Pathology of Lysosomal Storage DisordersBrain Pathology, 8
Dorothee Kalka, Carolina Reitzenstein, Jürgen Kopitz, Michael Cantz (2001)
The plasma membrane ganglioside sialidase cofractionates with markers of lipid rafts.Biochemical and biophysical research communications, 283 4
S. Walkley, M. Zervas, D. Siegel, K. Dobrenis (1999)
Gangliosides as Modulators of Dendritogenesis in Storage Disease-Affected and Normal Pyramidal NeuronsDevelopmental Neuropsychology, 16
D. Marks, R. Pagano (2002)
Endocytosis and sorting of glycosphingolipids in sphingolipid storage disease.Trends in cell biology, 12 12
K. Sandhoff, T. Kolter (1996)
Topology of glycosphingolipid degradation.Trends in cell biology, 6 3
K. Simons, J. Gruenberg (2000)
Jamming the endosomal system: lipid rafts and lysosomal storage diseases.Trends in cell biology, 10 11
K. Sandhoff, G. Echten (1994)
Chapter 2 Ganglioside metabolism: enzymology, topology and regulationProgress in Brain Research, 101
S. Liour, M. Jones, M. Suzuki, E. Bieberich, R. Yu (2001)
Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID.Molecular genetics and metabolism, 72 3
(2003)
Glycosphingolipid-cholesterol abnormalities in NPC2 deficient neurons appears equivalent to those occurring in neurons lacking NPC1, suggesting NPC1-NPC2 molecular cooperation. Program No. 537.15
M. Zervas, K. Dobrenis, S. Walkley (2001)
Neurons in Niemann‐Pick Disease Type C Accumulate Gangliosides as Well as Unesterified Cholesterol and Undergo Dendritic and Axonal AlterationsJNEN: Journal of Neuropathology & Experimental Neurology, 60
G. Schwarzmann, K. Sandhoff (1990)
Metabolism and intracellular transport of glycosphingolipids.Biochemistry, 29 49
M. Elleder, J. Sokolova, M. Hřebíček (1997)
Follow-up study of subunit c of mitochondrial ATP synthase (SCMAS) in Batten disease and in unrelated lysosomal disordersActa Neuropathologica, 93
V. Puri, R. Watanabe, M. Dominguez, Xiaofeng Sun, C. Wheatley, D. Marks, R. Pagano (1999)
Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseasesNature Cell Biology, 1
T. Cox (1996)
The metabolic and molecular bases of inherited disease: Vols I, II and III (7th edn): edited by Charles R. Scriver, Arthur L. Beaudet, William S. Sly and David Valle McGraw-Hill, 1995, £195.00 hbk (4605 pages) ISBN 0 07 909826 6Trends in Genetics, 12
S. Walkley (1995)
Pyramidal neurons with ectopic dendrites in storage diseases exhibit increased GM2 ganglioside immunoreactivityNeuroscience, 68
S. Walkley, M. Haskins, R. Shull (2004)
Alterations in neuron morphology in mucopolysaccharidosis type IActa Neuropathologica, 75
G. Constantopoulos, R. Eiben, I. Schafer (1978)
NEUROCHEMISTRY OF THE MUCOPOLYSACCHARIDOSES: BRAIN GLYCOSAMINOGLYCANS, LIPIDS AND LYSOSOMAL ENZYMES IN MUCOPOLYSACCHARIDOSIS TYPE III B (α‐N‐ACETYLGLUCOSAMINIDASE DEFICIENCY)Journal of Neurochemistry, 31
M. Allende, R. Proia (2002)
Lubricating cell signaling pathways with gangliosides.Current opinion in structural biology, 12 5
(1991)
Pathology of Niemann - Pick disease type C : studies of murine mutants
J. Ávila, J. Convit (1975)
Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro.The Biochemical journal, 152 1
S. Walkley (2003)
Neurobiology and cellular pathogenesis of glycolipid storage diseases.Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 358 1433
M. Zervas, S. Walkley (1999)
Ferret pyramidal cell dendritogenesis: Changes in morphology and ganglioside expression during cortical developmentJournal of Comparative Neurology, 413
L. Clarke, Christopher Russell, Scott Pownall, Cara Warrington, A. Borowski, James Dimmick, J. Toone, Frank Jirik (1997)
Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.Human molecular genetics, 6 4
Eric Berthiaume, Clifford Medina, Joel Swanson (1995)
Molecular size-fractionation during endocytosis in macrophagesThe Journal of Cell Biology, 129
J. Baumkötter, M. Cantz (1983)
Decreased ganglioside neuraminidase activity in fibroblasts from mucopolysaccharidosis patients. Inhibition of the activity in vitro by sulfated glycosaminoglycans and other compounds.Biochimica et biophysica acta, 761 2
SU Walkley (1995)
Pyramidal neurons with ectopic dendrites in storage diseases contain elevated levels of GM2 ganglioside, 68
EF Neufeld, J Muenzer (2001)
The metabolic and molecular bases of inherited disease
R. Pagano, V. Puri, M. Dominguez, D. Marks (2000)
Membrane Traffic in Sphingolipid Storage DiseasesTraffic, 1
Stanley Samuels, Korey, Jacqueline Gonatas, Robert Terry, M. Weiss (1963)
Studies in Tay-Sachs disease. IV. Membranous cytoplasmic bodies.Journal of neuropathology and experimental neurology, 22
Kint Ja, G. Dacremont, D. Carton, E. Orye, C. Hooft (1973)
Mucopolysaccharidosis: Secondarily Induced Abnormal Distribution of Lysosomal IsoenzymesScience, 181
S. Walkley, M. Zervas, Samson Wiseman (2000)
Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons.Cerebral cortex, 10 10
H. Maccioni, C. Giraudo, J. Daniotti (2002)
Understanding the Stepwise Synthesis of GlycolipidsNeurochemical Research, 27
G. Constantopoulos, A. Dekaban (1978)
NEUROCHEMISTRY OF THE MUCOPOLYSACCHARIDOSES: BRAIN LIPIDS AND LYSOSOMAL ENZYMES IN PATIENTS WITH FOUR TYPES OF MUCOPOLYSACCHARIDOSIS AND IN NORMAL CONTROLSJournal of Neurochemistry, 30
G. Echten, K. Sandhoff (1993)
Ganglioside metabolism. Enzymology, Topology, and regulation.The Journal of biological chemistry, 268 8
Riddhi Bhattacharyya, Briony Gliddon, T. Beccari, J. Hopwood, P. Stanley (2001)
A novel missense mutation in lysosomal sulfamidase is the basis of MPS III A in a spontaneous mouse mutant.Glycobiology, 11 1
The mucopolysaccharidoses (MPSs) are a complex family of lysosomal storage disorders characterized by failure to degrade heparan sulfate (HS) and/or other types of glycosaminoglycans (GAGs) secondary to the absence of specific lysosomal enzymes. An accompanying storage of glycosphingolipids (GSLs), most notably GM2 and GM3 gangliosides, has also been documented to occur in many types of MPS disease and is believed to be caused by secondary inhibition of GSL‐degradative enzymes by intracellular GAG accumulation. We have documented the presence of secondary ganglioside accumulation in mouse models of several MPS disorders (types I, IIIA, IIIB, and VII) and report that this storage is accompanied by sequestration of free cholesterol in a manner similar to that observed in primary gangliosidoses. Using confocal microscopy, we evaluated the cellular distribution of cholesterol, GM2 and GM3 gangliosides, and HS in brains of mice with MPS IIIA disease. Unexpectedly, we found that although both gangliosides often accumulated in the same neurons, they were consistently located in separate populations of cytoplasmic vesicles. Additionally, GM3 ganglioside only partially co‐localized with the primary storage material (HS), and cholesterol likewise only partially co‐localized with the GM2 and GM3 gangliosides. These findings raise significant questions about the mechanism(s) responsible for secondary accumulation of storage materials in MPS disease. Furthermore, given that GSLs and cholesterol are constituents of membrane rafts believed critical in signal transduction events in neurons, their co‐sequestration in individual neurons suggests the presence of defects in the composition, trafficking, and/or recycling of raft components and thus possible new mechanisms to explain neuronal dysfunction in MPS disorders. J. Comp. Neurol. 480:415–426, 2004. © 2004 Wiley‐Liss, Inc.
The Journal of Comparative Neurology – Wiley
Published: Aug 20, 2005
Keywords: ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.